Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a ...

Among significant research news last week, US CNS specialist Axsome Therapeutics released new Phase III data on its recently ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced that the EMERGE Phase 3 trial of Symbravo (MoSEIC meloxicam and rizatriptan ...

US CNS-focused biopharma firm Axsome Therapeutics today announced that the EMERGE Phase III trial of Symbravo (MoSEIC ...

Data from the Phase III EMERGE trial show treatment with Symbravo provided more rapid and sustained migraine relief with ...

Axsome Therapeutics (AXSM) announced that the EMERGE Phase 3 trial of SYMBRAVO in patients experiencing inadequate response to oral CGRP ...

A paper published in The Lancet showed that four out of four young children with Leber congenital amaurosis 4 retinal dystrophy due to a genetic deficiency of Aryl-hydrocarbon-interacting protein-like ...

The company received US approval for Symbravo, a novel oral acute treatment for migraine, and is preparing for its commercial launch. Axsome Therapeutics Inc (NASDAQ:AXSM) has a robust late-stage ...

On January 30, 2025, the U.S. Food and Drug Administration (FDA) approved Symbravo for the acute treatment of migraine with or without aura in adults. Symbravo represents a novel, multi-mechanistic ...

Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.

Most recently, we received US approval of Symbravo on January 30th for representing a novel oral acute treatment for migraine. Based on its clinical profile, Symbravo represents an important ...